SG Americas Securities LLC Buys 545,767 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

SG Americas Securities LLC increased its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 138.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 940,784 shares of the company's stock after buying an additional 545,767 shares during the period. SG Americas Securities LLC owned 0.68% of Compass Therapeutics worth $1,787,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Tower Research Capital LLC TRC grew its holdings in shares of Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after acquiring an additional 12,917 shares during the period. Independent Advisor Alliance bought a new stake in shares of Compass Therapeutics during the fourth quarter valued at approximately $26,000. BNP Paribas Financial Markets purchased a new stake in Compass Therapeutics in the fourth quarter worth $27,000. Mariner LLC bought a new position in Compass Therapeutics in the fourth quarter worth $30,000. Finally, Squarepoint Ops LLC purchased a new position in Compass Therapeutics during the fourth quarter valued at $35,000. 68.43% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CMPX. Leerink Partners raised shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Guggenheim cut their price objective on shares of Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Leerink Partnrs raised shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 1st. D. Boral Capital reiterated a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a report on Monday, April 28th. Finally, HC Wainwright restated a "buy" rating and issued a $24.00 price target on shares of Compass Therapeutics in a research note on Monday, April 21st. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $13.13.

Compass Therapeutics Price Performance

NASDAQ:CMPX opened at $2.41 on Monday. The stock has a market cap of $333.26 million, a price-to-earnings ratio of -6.51 and a beta of 1.41. The company's 50 day moving average price is $2.00 and its 200-day moving average price is $2.20. Compass Therapeutics, Inc. has a 52 week low of $0.77 and a 52 week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). As a group, sell-side analysts anticipate that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Insider Activity at Compass Therapeutics

In related news, insider Jonathan Anderman purchased 20,000 shares of Compass Therapeutics stock in a transaction dated Monday, April 7th. The stock was purchased at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the purchase, the insider now directly owns 21,000 shares of the company's stock, valued at $32,340. The trade was a 2,000.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. 29.80% of the stock is currently owned by insiders.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.